Can a Two-Drug combo outsmart resistant lung cancer?

NCT ID NCT04085315

Completed Disease control Sponsor: Collin Blakely Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding an experimental drug called alisertib to the standard treatment osimertinib can help people with stage IV EGFR-mutant lung cancer. The study aims to find the safest dose of alisertib when given with osimertinib and to see how the combination affects tumors. Participants receive both drugs by mouth, and researchers monitor side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alisertib combined with osimertinib
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with EGFR-mutant lung cancer that has spread.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it's too soon to know if the combination will work. Side effects may limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR GENE MUTATION LUNG CANCER METASTATIC

Contacts and locations

Locations

University of California, San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.